SwePub
Sök i LIBRIS databas

  Extended search

(WFRF:(Barrett J)) pers:(Barrett John)
 

Search: (WFRF:(Barrett J)) pers:(Barrett John) > (2014) > Hematopoietic stem-...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Ustun, Celalettin (author)

Hematopoietic stem-cell transplantation for advanced systemic mastocytosis

  • Article/chapterEnglish2014

Publisher, publication year, extent ...

  • 2014
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-245271
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-245271URI
  • https://doi.org/10.1200/JCO.2014.55.2018DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:129885760URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • PURPOSE: Advanced systemic mastocytosis (SM), a fatal hematopoietic malignancy characterized by drug resistance, has no standard therapy. The effectiveness of allogeneic hematopoietic stem-cell transplantation (alloHCT) in SM remains unknown.PATIENTS AND METHODS: In a global effort to define the value of HCT in SM, 57 patients with the following subtypes of SM were evaluated: SM associated with clonal hematologic non-mast cell disorders (SM-AHNMD; n = 38), mast cell leukemia (MCL; n = 12), and aggressive SM (ASM; n = 7). Median age of patients was 46 years (range, 11 to 67 years). Donors were HLA-identical (n = 34), unrelated (n = 17), umbilical cord blood (n = 2), HLA-haploidentical (n = 1), or unknown (n = 3). Thirty-six patients received myeloablative conditioning (MAC), and 21 patients received reduced-intensity conditioning (RIC).RESULTS: Responses in SM were observed in 40 patients (70%), with complete remission in 16 patients (28%). Twelve patients (21%) had stable disease, and five patients (9%) had primary refractory disease. Overall survival (OS) at 3 years was 57% for all patients, 74% for patients with SM-AHNMD, 43% for those with ASM, and 17% for those with MCL. The strongest risk factor for poor OS was MCL. Survival was also lower in patients receiving RIC compared with MAC and in patients having progression compared with patients having stable disease or response.CONCLUSION: AlloHCT was associated with long-term survival in patients with advanced SM. Although alloHCT may be considered as a viable and potentially curative therapeutic option for advanced SM in the meantime, given that this is a retrospective analysis with no control group, the definitive role of alloHCT will need to be determined by a prospective trial.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Reiter, Andreas (author)
  • Scott, Bart L (author)
  • Nakamura, Ryotaro (author)
  • Damaj, Gandhi (author)
  • Kreil, Sebastian (author)
  • Shanley, Ryan (author)
  • Hogan, William J (author)
  • Perales, Miguel-Angel (author)
  • Shore, Tsiporah (author)
  • Baurmann, Herrad (author)
  • Stuart, Robert (author)
  • Gruhn, Bernd (author)
  • Doubek, Michael (author)
  • Hsu, Jack W (author)
  • Tholouli, Eleni (author)
  • Gromke, Tanja (author)
  • Godley, Lucy A (author)
  • Pagano, Livio (author)
  • Gilman, Andrew (author)
  • Wagner, Eva Maria (author)
  • Shwayder, Tor (author)
  • Bornhäuser, Martin (author)
  • Papadopoulos, Esperanza B (author)
  • Böhm, Alexandra (author)
  • Vercellotti, Gregory (author)
  • Van Lint, Maria Teresa (author)
  • Schmid, Christoph (author)
  • Rabitsch, Werner (author)
  • Pullarkat, Vinod (author)
  • Legrand, Faezeh (author)
  • Yakoub-Agha, Ibrahim (author)
  • Saber, Wael (author)
  • Barrett, John (author)
  • Hermine, Olivier (author)
  • Hägglund, HansKarolinska Institutet,Uppsala universitet,Hematologi,Karolinska University Hospital, Stockholm, Sweden(Swepub:uu)hanha689 (author)
  • Sperr, Wolfgang R (author)
  • Popat, Uday (author)
  • Alyea, Edwin P (author)
  • Devine, Steven (author)
  • Deeg, H Joachim (author)
  • Weisdorf, Daniel (author)
  • Akin, Cem (author)
  • Valent, Peter (author)
  • Uppsala universitetHematologi (creator_code:org_t)

Related titles

  • In:Journal of Clinical Oncology32:29, s. 3264-32740732-183X1527-7755

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view